Consistent with previous findings in other carcinomas, inactivating alterations in TP53 were highly enriched in MYBL2 High lung adenocarcinomas (36); 76% of MYBL2 High tumors contained TP53 mutations, compared to only 19% of MYBL2 Low (q = 4.2e–4, one-sided Fisher Exact test, Benjamini-Hochberg corrected) (Figure S3B). The gene discussed is TP53; the disease is carcinoma.